Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
Elizabeth Sloan, MD |
ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…
An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.
Lisa Stamp, MBChB, PhD |
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD |
The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…
Mary Choy, PharmD, BCGP, FASHP |
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…